Kinnate Biopharma Inc.·4

Mar 15, 5:01 PM ET

Williams Richard Thomas 4

4 · Kinnate Biopharma Inc. · Filed Mar 15, 2022

Insider Transaction Report

Form 4
Period: 2022-03-11
Williams Richard Thomas
Chief Medical Officer
Transactions
  • Purchase

    Common Stock

    2022-03-11$8.64/sh+15,000$129,60017,333 total
  • Purchase

    Common Stock

    2022-03-14$8.37/sh+25,000$209,25042,333 total
Footnotes (3)
  • [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.42 to $8.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
  • [F2]Includes 1,769 shares acquired under the Issuers Employee Stock Purchase Plan (the "Plan") in May 2021 and 564 shares acquired under the Plan in November 2021.
  • [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.25 to $8.50, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION